{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:28:37Z","timestamp":1790234917173,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017104","name":"Yokohama City University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10157-024-02532-4","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T05:01:26Z","timestamp":1720242086000},"page":"1282-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip"],"prefix":"10.1007","volume":"28","author":[{"given":"Rina","family":"Kawano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Haze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2892-3775","authenticated-orcid":false,"given":"Akira","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Haruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Hirawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet"},{"key":"2532_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17446651.2022.2099373","volume":"17","author":"Y Kurata","year":"2022","unstructured":"Kurata Y, et al. Dapagliflozin for the treatment of chronic kidney disease. Expert Rev Endocrinol Metab. 2022;17:275\u201391.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2532_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2532_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.hfc.2022.03.005","volume":"18","author":"V Vallon","year":"2022","unstructured":"Vallon V. Renoprotective effects of SGLT2 inhibitors. Heart Fail Clin. 2022;18:539\u201349.","journal-title":"Heart Fail Clin"},{"key":"2532_CR5","first-page":"189","volume":"34","author":"H Fattah","year":"2019","unstructured":"Fattah H, et al. How do kidneys adapt to a deficit or loss in nephron number? Physiology (Bethesda). 2019;34:189\u201397.","journal-title":"Physiology (Bethesda)"},{"key":"2532_CR6","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/biomedicines10102458","volume":"10","author":"R Skrabic","year":"2022","unstructured":"Skrabic R, et al. SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice. Biomedicines. 2022;10:2458.","journal-title":"Biomedicines"},{"key":"2532_CR7","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/ijms21217833","volume":"21","author":"YC Hou","year":"2020","unstructured":"Hou YC, et al. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci. 2020;21:7833.","journal-title":"Int J Mol Sci"},{"key":"2532_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"issue":"6","key":"2532_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","volume":"2","author":"AY Meraz-Mu\u00f1oz","year":"2021","unstructured":"Meraz-Mu\u00f1oz AY, et al. eGFR Decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360. 2021;2(6):1042\u20137.","journal-title":"Kidney360"},{"key":"2532_CR10","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/ASN.2022030306","volume":"33","author":"N Jongs","year":"2022","unstructured":"Jongs N, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33:2094\u2013107.","journal-title":"J Am Soc Nephrol"},{"key":"2532_CR11","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, et al. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology. 2018;57:vii54\u20138.","journal-title":"Rheumatology"},{"key":"2532_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15623","author":"K Nakhleh","year":"2024","unstructured":"Nakhleh K, et al. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15623. (Online ahead of print).","journal-title":"Diabetes Obes Metab"},{"key":"2532_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, et al. Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99:750\u201362.","journal-title":"Kidney Int"},{"key":"2532_CR14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","volume":"16","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, et al. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol. 2021;16:1278\u201380.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2532_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-022-02277-y","volume":"27","author":"R Shibata","year":"2023","unstructured":"Shibata R, et al. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. Clin Exp Nephrol. 2023;27:44\u201353.","journal-title":"Clin Exp Nephrol"},{"key":"2532_CR16","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1001\/archinte.168.20.2212","volume":"168","author":"DE Rifkin","year":"2008","unstructured":"Rifkin DE, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168:2212\u20138.","journal-title":"Arch Intern Med"},{"key":"2532_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129036","volume":"10","author":"M Baba","year":"2015","unstructured":"Baba M, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS ONE. 2015;10: e0129036.","journal-title":"PLoS ONE"},{"key":"2532_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cardfail.2016.09.006","volume":"23","author":"K Damman","year":"2017","unstructured":"Damman K, et al. Progression of renal impairment and chronic kidney disease in chronic heart failure: an analysis from GISSI-HF. J Card Fail. 2017;23:2\u20139.","journal-title":"J Card Fail"},{"key":"2532_CR19","unstructured":"Committee for Medicinal Products for Human Use. Guideline on Adjustment for Baseline Covariates in Clinical Trials. 2015. https:\/\/www.ema.europa.eu\/en\/adjustment-baseline-covariates-clinical-trials-scientific-guideline"},{"key":"2532_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41371-021-00595-4","volume":"36","author":"T Haze","year":"2022","unstructured":"Haze T, et al. Association of achieved blood pressure after treatment for primary aldosteronism with long-term kidney function. J Hum Hypertens. 2022;36:904\u201310.","journal-title":"J Hum Hypertens"},{"key":"2532_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2021.03.033","volume":"324","author":"T Haze","year":"2021","unstructured":"Haze T, et al. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis. 2021;324:84\u201390.","journal-title":"Atherosclerosis"},{"key":"2532_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamacardio.2018.1233","volume":"3","author":"T Fujiwara","year":"2018","unstructured":"Fujiwara T, et al. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a japanese general practice population. JAMA Cardiol. 2018;3:583\u201390.","journal-title":"JAMA Cardiol"},{"key":"2532_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/EDE.0b013e31815be000","volume":"19","author":"PG Arbogast","year":"2008","unstructured":"Arbogast PG, et al. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology. 2008;19:30\u20137.","journal-title":"Epidemiology"},{"key":"2532_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/aje\/kwx032","volume":"185","author":"R Wyss","year":"2017","unstructured":"Wyss R, et al. The \u201cdry-run\u201d analysis: a method for evaluating risk scores for confounding control. Am J Epidemiol. 2017;185:842\u201352.","journal-title":"Am J Epidemiol"},{"key":"2532_CR25","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/ijms23073915","volume":"23","author":"G Capolongo","year":"2022","unstructured":"Capolongo G, et al. A shared nephroprotective mechanism for renin-angiotensin-system inhibitors, sodium-glucose co-transporter 2 inhibitors, and vasopressin receptor antagonists: immunology meets hemodynamics. Int J Mol Sci. 2022;23:3915.","journal-title":"Int J Mol Sci"},{"key":"2532_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020237","volume":"10","author":"Y Xie","year":"2021","unstructured":"Xie Y, et al. Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes. J Am Heart Assoc. 2021;10: e020237.","journal-title":"J Am Heart Assoc"},{"key":"2532_CR27","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/jcm9072243","volume":"9","author":"L De Nicola","year":"2020","unstructured":"De Nicola L, et al. Nephroprotection by sglt2 inhibition: back to the future? J Clin Med. 2020;9:2243.","journal-title":"J Clin Med"},{"key":"2532_CR28","volume":"22","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, et al. Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria. J Clin Transl Endocrinol. 2020;22: 100244.","journal-title":"J Clin Transl Endocrinol"},{"key":"2532_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1751-7176.2008.00023.x","volume":"10","author":"DL Cohen","year":"2008","unstructured":"Cohen DL, et al. What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker? J Clin Hypertens (Greenwich). 2008;10:803\u201380.","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02532-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T03:04:34Z","timestamp":1733454274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02532-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at Yokohama City University (IRB approval no. F230700037) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}